 We propose a double-blind, randomized trial to assess the safety of CC-11050 in adults with HIV infection who have taken ART for at least 1 year and have suppressed plasma viremia. Enrolled subjects will be randomized 2:1 to 200 mg CC-11050 or placebo twice daily for 12 weeks. Participants will be evaluated at weeks 0, 2, 4, 8, 12 and 16. Changes in in plasma HIV-1 RNA levels by clinical assay, CD4 T cell counts and percentages, and the effect on markers of systemic inflammation e.g., TNF, IL-6, CRP, IFNg, sCD14, D-dimer will be measured. The effect of CC-11050 on cellular immune activation T cells and monocytes, and on viral reservoirs cell associated HIV DNA and RNA will also be assessed. 